The "Down Syndrome Abortion Ban" Uncovers A Difficult Truth About Pro-Choice Politics & Disability
By Hillary Savoie,
Romper
| 01. 04. 2018
When I saw the email asking me to write about the recent Ohio law that makes performing an abortion after the prenatal diagnosis of Down syndrome a felony, signed last week by Governor Kasich, I winced. While I have a lot to say about disability and abortion, I have engaged in enough discussions about this topic to know that what I have to say risks making me enemies of just about everyone.
Let me be clear from the outset: In my opinion, the Ohio law in question — which takes effect in March and will punish doctors with hefty fines, loss of their medical license, and jail time for performing an abortion following a diagnosis of Down syndrome — is a stupendously misguided bill. It has little to do with substantively protecting the lives of people with Down syndrome. Instead it has everything to do with using people with Down syndrome as a tool to achieve a political goal. At the same time, I also believe that this bill gestures toward a serious ethical question that our society...
Related Articles
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Elise Kinsella, ABC News | 06.15.2025
When *Sarah and her partner needed fertility testing, it was Monash IVF that the pair turned to.
"Having a quick browse online, Monash IVF was one of the most prominent ones that came up on Google search and after contacting...
By Hilary Bowman-Smart and Craig Stanbury, The Conversation | 06.12.2025
By Antonio Regalado, MIT Technology Review | 06.05.2025
Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready to fund a US startup focused on gene-editing human embryos. If he goes forward, it would be the first major commercial investment in one of medicine’s most...